论文部分内容阅读
目的分析评价重组人白介素-11(rhIL-11)对急性白血病患者首次诱导化疗后血小板减少的影响和治疗效果。方法将44例初治急性白血病患者随机分为重组人白介素-11治疗组和单纯血小板输注组,计数两组患者在接受首次诱导缓解治疗期间血小板数值的变化和恢复至≥20×109/L,≥50×109/L,≥100×109/L的天数,对重组人白介素-11的治疗效果进行比较分析。结果重组人白介素-11治疗组的血小板下降谷值较单纯血小板输注组有所提高,P值<0.05。血小板恢复至≥20×109/L,≥50×109/L,≥100×109/L的天数均短于单纯血小板输注组,人均输注血小板数量减少,P值<0.05。结论重组人白介素-11能够有效地改善急性白血病化疗后的血小板减少,提高血小板恢复的速度,减少了患者对输血的依赖。
Objective To evaluate the effect of recombinant human interleukin-11 (rhIL-11) on thrombocytopenia after first induction chemotherapy in patients with acute leukemia and its therapeutic effect. Methods Forty-four patients with newly diagnosed acute leukemia were randomly divided into recombinant human IL-11-treated group and simple platelet transfusion group. Changes in platelet count and recovery to ≥20 × 109 / L during the first induction remission , ≥50 × 109 / L, ≥100 × 109 / L days, the therapeutic effect of recombinant human interleukin-11 were compared. Results In the recombinant human interleukin-11 treatment group, the valley value of platelet decline was higher than that of platelet transfusion group (P <0.05). Platelets recovered to ≥20 × 109 / L, ≥50 × 109 / L, ≥100 × 109 / L days were shorter than simple platelet transfusion group, per capita transfusion platelet number decreased, P value <0.05. Conclusion Recombinant human interleukin-11 can effectively improve the thrombocytopenia after acute leukemia chemotherapy, increase the rate of platelet recovery and reduce the patient’s dependence on blood transfusion.